| T. Rowe Price Health Sciences Port |
|
 |
|
| Release date as of 2025-04-30. Data on page is subject to change. |
|
|
| Fees and Expenses |
Taken from prospectus dated 2024-05-01 |
|
| Maximum Fees |
| Administrative |
--- |
| Management |
0.95%
|
| 12b-1 |
--- |
|
|
| Actual Fees |
| 12b-1 |
--- |
| Management |
0.66%
|
| Expense Ratio |
0.88%
|
(taken from annual report dated 2024-12-31) |
| Total Annual Operating Expense |
0.86%
|
|
|
|
|
Type |
Date |
% |
| --- |
--- |
--- |
--- |
|
|
|
|
|
| Inception Date: 2000-12-29 |
|
|
|
|
| Mngr Name |
Jason(Jay) Nogueira |
| Mngr Start Date |
2025-03-24 |
|
| Biography |
| Mr. Nogueira has been chairman of the committee since the fund’s inception. He joined the Firm in 2004 and has a total of 15 years of investment experience. Since joining the T. Rowe, he has served as a portfolio manager (beginning in 2016) and as an equity research analyst and assisted other portfolio managers in executing certain of the Firm’s equity strategies.
Nogueira holds the Chartered Financial Analyst designation. |
|
|
| Mngr Name |
Ziad Bakri |
| Mngr Start Date |
2016-04-01 |
|
| Biography |
| Ziad Bakri joined T. Rowe Price in 2011 and has since been a key member of the healthcare research team, influencing investment decisions and making significant contributions to the stock selections. Ziad has had a long track record of analyzing biotechnology companies, a key sector within the healthcare industry. Ziad brings a unique perspective to his new role, having been a medical doctor and an emergency medicine resident at the Royal London Hospital before beginning his investment career. Prior to joining T. Rowe Price, Ziad held biotechnology equity research and healthcare investment ban |
|
|
|
| T. Rowe Price Associates, Inc. |
|
|
© Copyright 2025 Morningstar, Inc. All rights reserved. Morningstar, the Morningstar logo, Morningstar.com, Morningstar Tools are either trademark or service marks of Morningstar, Inc. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or any losses arising from any use of information. Past performance is no guarantee of future performance. |
|
Past performance is no guarantee of future results.
Returns will vary and shares may be worth more or less than their original cost when sold.
|
|
